Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com - Revvity, Inc. (NYSE:RVTY) reported third-quarter adjusted earnings that exceeded analyst expectations on Monday, prompting the company to raise its full-year profit outlook while maintaining its organic growth forecast.
Shares of the company edged up 0.72% in pre-market trading following the announcement.
The health science solutions provider posted adjusted earnings of $1.18 per share for the third quarter, surpassing the analyst consensus of $1.14. Revenue came in at $699 million, essentially in line with analyst expectations of $699.39 million and representing a 2% increase from the same period last year. Organic revenue growth was 1% YoY.
"We performed well during the third quarter as a number of key innovations and strategic partnerships have begun to come to fruition," said Prahlad Singh, president and chief executive officer of Revvity. "Our strong level of execution is positioning the Company for even greater success in 2026 and beyond."
The company’s Diagnostics segment led growth with a 3% revenue increase to $356 million, while the Life Sciences segment saw a 1% rise to $343 million. However, adjusted operating margins declined in both segments compared to the prior year.
Revvity updated its full-year 2025 revenue guidance to $2.83-$2.88 billion, reflecting recent foreign currency exchange rate changes, while reaffirming organic growth of 2-4%. The company raised its adjusted EPS outlook to $4.90-$5.00, above the analyst consensus of $4.87.
In a move that may please investors, Revvity’s Board of Directors authorized a new two-year $1 billion share repurchase program, replacing the remainder of the prior repurchase program announced in October 2024.